March Private Market UpdateFebruary shows slight uptick in Forge’s investor interest prior to bank turbulence
March Private Market Update
Ginkgo Bioworks was founded in 2008 by Jason Kelly, Reshma Shetty, Barry Canton, Austin Che, and Tom Knight. The company has not officially endorsed a plan to participate in an IPO.
Ginkgo specializes in leveraging biological processes in organisms to meet the needs of their clients in industries ranging from cosmetics to food goods. Their website claims the firm’s expertise is in cultured ingredients, strain improvement, and enzymes. The company has raised nearly $800 million in Venture Capital funding from investors including Reshape Holdings, T. Rowe Price, Innovation Camp, Illumia, Power Gate Ventures, Alrai Capital, OS Fund, Azure Capital Partners, Data Collective, Felicis Ventures, Vast Ventures, and Y Combinator. Per company press releases, Ginko last raised a Series E expansion in May 2020 bringing the round total to $360 million at a post-money valuation of nearly $5 billion.
DNA
1.28 as of 3/17/23
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 5/28/2020 | Series E | $4.89B | $XXX.XX | $XXX.XX |
| 12/14/2017 | Series D | $1.57B | $XXX.XX | $XXX.XX |
| 6/8/2016 | Series C | $450MM | $XXX.XX | $XXX.XX |
| 7/8/2015 | Series B | $200MM | $XXX.XX | $XXX.XX |
